Cowen and Company’s Kyntra Bio KYNB Stock Holding History

Cowen and Company’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-400	Closed	-$29K	–	444
2020 Q3	$29K	Buy	+400	New	+$430K	﹤0.01%	330

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Cowen and Company's KYNB Position: Q4 2020 in Review

Cowen and Company sold out of Kyntra Bio (KYNB) in Q4 2020, closing a stake of 61 shares — an estimated $63K sold.

Cowen and Company first reported a position in KYNB in Q3 2020 and held it in 1 quarter. The position peaked at $63K in Q3 2020. 207 funds tracked by Wall St. Rank hold KYNB as of Q4 2020.

Cowen and Company reported no remaining Kyntra Bio position as of Q4 2020 after selling out during the quarter.
Cowen and Company sold 61 Kyntra Bio shares in Q4 2020, an estimated $63K.
Cowen and Company first reported a position in Kyntra Bio in Q3 2020 and held it in 1 quarter.
Cowen and Company's Kyntra Bio position peaked at $63K in Q3 2020.
207 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2020.

Based on Cowen and Company's 13F filing for Q4 2020, filed 8 Feb 2021.